Emerging in the arena of obesity therapy, retatrutide is a distinct strategy. Different from many available medications, retatrutide functions as a twin agonist, simultaneously engaging both GLP-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) binding sites. The simultaneous engagement fosters several advantageous effec… Read More